--- title: "Dare Bioscience (DARE) news: reverse split and delisting" url: "https://aibio.space/companies/dare-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DARE reverse split, delisting, going concern, offering, convertible notes and Nasdaq notice news: Daré Bioscience gets Nasdaq notice for stock below $1.00." --- DARE Dare Bioscience, Inc. NASDAQ · United States # Dare Bioscience (DARE) news DARE reverse split, delisting and going concern news Listings · 2026-10-02 ## [Daré Bioscience gets Nasdaq notice for stock below $1.00](https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stock-below-1-00/) Daré Bioscience has until March 29, 2027 to show a $1.00 closing bid price for 10 consecutive business days. A second 180-day period is possible only if it meets the other listing standards and says it will cure the shortfall, by a reverse split if needed. Its cash fell to $12.6 million by June 30, 2026. ## Latest Dare Bioscience news 1. 2026-08-14 Financings [Daré prices $6.0M registered direct with warrants on twice the shares](https://aibio.space/news/dare-prices-6-0m-registered-direct-warrants-twice-shares/) Daré Bioscience sold 4.38M shares at $1.37 and gave buyers two warrant series covering 8.76M more, while Nasdaq reviews its listing and cash runs into Q4. 2. 2026-07-17 Listings [Daré Bioscience gets Nasdaq notice on stockholders' equity, plans hearing](https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stockholders-equity-plans-hearing/) Nasdaq told Daré Bioscience (Nasdaq: DARE) on July 13, 2026 that it no longer meets Listing Rule 5550(b). The company intends to request a hearing, which would stay delisting while the panel decides. 3. 2026-04-20 Financings [Daré Bioscience closes sale of 20,000 units in Regulation A preferred stock and warrant offering](https://aibio.space/news/dare-bioscience-closes-sale-20-000-units-regulation-preferred-stock/) Daré issued 20,000 Investor Units at $5.00 each, with one Series A Convertible Preferred share and two warrants per unit. The offering is for up to 4,854,000 units, and the company's auditor has raised going concern doubt. ## Dare Bioscience at a glance - **Ticker**: DARE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $12.6 million ### Related companies - [Oric Pharmaceuticals](https://aibio.space/companies/oric-pharmaceuticals/) NASDAQ: ORIC - [Journey Medical](https://aibio.space/companies/journey-medical/) NASDAQ: DERM - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [Liquidia](https://aibio.space/companies/liquidia/) NASDAQ: LQDA - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) NASDAQ: ACTU - [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) OTC: LIPO - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) AMEX: PLX - [EyePoint](https://aibio.space/companies/eyepoint/) NASDAQ: EYPT ### Also on NASDAQ - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) XLO - [Lantern Pharma](https://aibio.space/companies/lantern-pharma/) LTRN - [Senti Biosciences Holdings](https://aibio.space/companies/senti-biosciences/) SNTI - [BioCardia](https://aibio.space/companies/biocardia/) BCDA - [Nyxoah SA](https://aibio.space/companies/nyxoah/) NYXH - [Chemomab Therapeutics](https://aibio.space/companies/chemomab-therapeutics/) CMMB ## What Dare Bioscience does Daré Bioscience, Inc. is a purpose-driven health biotech company focused on women's health, with programs covering contraception, menopause, pelvic pain, fertility, vaginal health and infectious disease. For select proprietary formulations it pursues both traditional FDA approval and earlier market access through outsourcing facilities registered under Section 503B of the FDCA. In December 2025 it began commercialization of DARE to PLAY Sildenafil Cream, a topically applied sildenafil formulation designed to improve female sexual arousal. Its first DARE to RESTORE product, Flora Sync LF5, a vaginal probiotic suppository, is expected to become commercially available in the U.S. in the second quarter of 2026. Its first FDA-approved product, XACIATO (clindamycin phosphate) vaginal gel 2%, was approved in December 2021 for bacterial vaginosis. Organon licensed worldwide rights to XACIATO in 2022, and in April 2024 Daré sold its rights to royalty and milestone payments on XACIATO net sales to XOMA (US) LLC. Its most advanced candidates include Ovaprene, a hormone-free monthly intravaginal contraceptive in a pivotal Phase 3 study, and DARE-HRT1, an intravaginal ring for menopausal hormone therapy. The company does not intend to build its own sales force. | Product or program | What it is | Stage | |---|---|---| | Ovaprene | Hormone-free monthly intravaginal contraceptive | pivotal Phase 3 clinical study | | DARE to PLAY Sildenafil Cream | 3.6% topical sildenafil cream for female sexual arousal | commercialization initiated December 2025 | | Flora Sync LF5 | Vaginal probiotic suppository in the DARE to RESTORE line | expected commercially available in the U.S. in second quarter 2026 | | DARE-HRT1 | Intravaginal ring delivering estradiol and progesterone for hot flashes | | | XACIATO | Clindamycin phosphate vaginal gel 2% for bacterial vaginosis | approved in the US | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm). ## Dare Bioscience annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$5.5 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | [$14.3 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | | Net income (loss) | [-$13.4 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | [-$4.1 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | | Cash from operations | [-$9.9 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | [$5.5 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | | Cash and equivalents | [$24.7 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000043/) | [$15.7 million](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Dare Bioscience Did Dare Bioscience do a reverse stock split? Our latest story on this, dated Oct 2, 2026: "Daré Bioscience gets Nasdaq notice for stock below $1.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stock-below-1-00/). Was Dare Bioscience delisted? Our latest story on this, dated Jul 17, 2026: "Daré Bioscience gets Nasdaq notice on stockholders' equity, plans hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stockholders-equity-plans-hearing/). Has Dare Bioscience issued a going-concern warning? Our latest story on this, dated Apr 20, 2026: "Daré Bioscience closes sale of 20,000 units in Regulation A preferred stock and warrant offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dare-bioscience-closes-sale-20-000-units-regulation-preferred-stock/). Has Dare Bioscience raised money recently? Our latest story on this, dated Aug 14, 2026: "Daré prices $6.0M registered direct with warrants on twice the shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dare-prices-6-0m-registered-direct-warrants-twice-shares/). Has Dare Bioscience sold convertible notes? Our latest story on this, dated Apr 20, 2026: "Daré Bioscience closes sale of 20,000 units in Regulation A preferred stock and warrant offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dare-bioscience-closes-sale-20-000-units-regulation-preferred-stock/). Has Dare Bioscience received a Nasdaq deficiency notice? Our latest story on this, dated Oct 2, 2026: "Daré Bioscience gets Nasdaq notice for stock below $1.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stock-below-1-00/). What is the ticker symbol of Dare Bioscience? Dare Bioscience, Inc. trades under the ticker DARE on NASDAQ. Where is Dare Bioscience listed? Dare Bioscience, Inc. is listed on NASDAQ. What is the SEC CIK of Dare Bioscience? The SEC Central Index Key (CIK) for Dare Bioscience, Inc. is 1401914. Its filings are on SEC EDGAR. How many shares does Dare Bioscience have outstanding? 15,289,502 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Dare Bioscience listed under? Our directory records Dare Bioscience, Inc. under United States. What does Dare Bioscience do? Our directory classifies Dare Bioscience, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Dare Bioscience? The ISIN recorded for Dare Bioscience, Inc. is US23666P2002. Does aibio.space cover Dare Bioscience? aibio.space lists Dare Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Dare Bioscience incorporated? SEC records list its state or country of incorporation as DE. ## Investor discussion: Dare Bioscience Members talk about Dare Bioscience (DARE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Dare Bioscience, newest first. Each line links the filing it comes from. 1. 2026-10-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000052/dare-20260928.htm) 2. 2026-08-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1401914/000149315226038646/form424b5.htm) 3. 2026-07-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000040/dare-20260713.htm) 4. 2026-01-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/form8-k.htm) 5. 2025-12-01 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/ex99-1.htm) 6. 2025-07-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000149315225011402/form8-k.htm) 7. 2025-07-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000164117225020295/form8-k.htm) 8. 2025-06-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000164117225016374/form8-k.htm) 9. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000164117225003887/form8-k.htm) 10. 2025-02-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1401914/000149315225006958/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DARE on TradingView](https://www.tradingview.com/symbols/NASDAQ-DARE/). ## SEC filings and registration - **SEC name**: Dare Bioscience, Inc. - **CIK**: 1401914 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: DARE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3655 NOBEL DRIVE, SAN DIEGO, CA, 92122 - **Phone**: 858-926-7655 - **Shares outstanding**: 15,289,502 as of 2026-08-12 (10-Q filed 2026-08-13) - **Former names**: Cerulean Pharma Inc.; Tempo Pharmaceuticals Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1401914/000149315226045977/formdef14a.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000052/dare-20260928.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1401914/000149315226045275/form8-k.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000050/dare-20260910.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1401914/000149315226041904/form8-k.htm) filed 2026-09-09 - [S-1](https://www.sec.gov/Archives/edgar/data/1401914/000149315226040265/forms-1.htm) filed 2026-08-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1401914/000149315226038649/form8-k.htm) filed 2026-08-17 - [424B5](https://www.sec.gov/Archives/edgar/data/1401914/000149315226038646/form424b5.htm) filed 2026-08-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001401914), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Dare Bioscience, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DARE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Dare Bioscience, Inc. - **Ticker**: DARE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US23666P2002 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DARE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dare-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Dare Bioscience (DARE) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/dare-bioscience/